Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Kenya's economy faces climate change risks: World Bank
-
Warner Bros. 'reviewing' new takeover bid from Paramount
-
UK govt says will release files on 'rude' ex-prince Andrew
-
Stocks bounce as traders assess AI fallout, tariffs
-
Senegal PM vows to double penalty for same-sex relations
-
Novo Nordisk to slash prices of weightloss drugs in US
-
Greece set new tourism record in 2025
-
Stocks fluctuate as traders assess AI fallout, tariffs
-
China targets Japanese companies over military ties
-
Asian markets mixed as traders weigh AI and tariffs outlook
-
Australia buys parts for future AUKUS sub reactor
-
Brazil court to try politicians over hit on black councilwoman
-
Despite drop in 2025, Russian oil exports exceed pre-war volumes: report
-
Australian PM seeks removal of UK's Andrew from line of succession
-
Winter storm blankets US northeast as travel bans imposed
-
YouTube exec says goal was viewer value not addiction
-
US stocks tumble on tariff fog, worries over AI
-
US winter storm brings rare hush to snowy New York
-
Canada summons OpenAI over failure to report mass shooter
-
Panama takes control of canal ports from CK Hutchison
-
Snowstorm blankets US northeast as New York sees travel ban
-
Canada PM heads to Asia seeking new trade partners as US ties fray
-
Where do Ukraine and Russia stand after four years of war?
-
Police investigating racist abuse of Premier League quartet
-
Nigeria paid Boko Haram ransom for kidnapped pupils: intel sources
-
New York orders citywide travel ban as major storm hits US
-
Asian stocks rally after Trump's Supreme Court tariffs blow
-
New York mayor orders citywide travel ban as major storm hits US
-
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B
-
GA-ASI Announces YFQ-42A Dark Merlin
-
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise
-
Are Major LGBTQ Dating Apps a Hidden Privacy Risk?
-
'GOAT' battles to top of N. America box office
-
Six stand-out moments from the 2026 Winter Olympics
-
St Francis relics go on public show for first time in Italy
-
Brazil's Lula urges Trump to treat all countries equally
-
Copper, a coveted metal boosting miners
-
AI agent invasion has people trying to pick winners
-
Cuban Americans keep sending help to the island, but some cry foul
-
Klaebo makes Olympic history as Gu forced to wait
-
NASA chief rules out March launch of Moon mission over technical issues
-
AI revolution looms over Berlin film fest
-
Libya's Ramadan celebrations tempered by economic woes
-
French volunteer bakes for Ukraine amid frosts and power outages
-
Gu shoots for elusive gold as Klaebo makes Olympic history
-
Global summit calls for 'secure, trustworthy and robust AI'
-
Trump, once unstoppable, hits snag after snag ahead of major US address
-
Tomb more than 1,000 years old found in Panama
-
Battered by Gaza war, Israel's tech sector in recovery mode
-
'Not the end': Small US firms wary but hopeful on tariff upheaval
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
H.Meyer--CPN